Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ckj/sft078 http://scihub22266oqcxt.onion/10.1093/ckj/sft078 C4438394!4438394!26120441     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Kidney+J 2013 ; 6 (5): 484-5 Nephropedia Template TP {{tp|p=26120441|t=2013. Eculizumab and drug-induced haemolytic?uraemic syndrome |pdf=|usr=}}{{26120441}} gab.com Text Eculizumab and drug-induced haemolytic uraemic syndrome JO: Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=26120441 #FOAvip The monoclonal anti-C5 antibody eculizumab has been successfully tested in atypical haemolytic-uraemic syndrome (aHUS), with or without mutations in the regulatory proteins of the alternative pathway of the complement, and less convincingly in enterohaemorrhagic Escherichia coli-associated HUS. Here, we report a patient with mitomycin-C-induced HUS unresponsive to plasma exchanges. Eculizumab infusion was followed by a dramatic improvement of haematological parameters and renal function, suggesting a role of complement blockade in the management of refractory, drug-related HUS. Twit Text FOAVip Eculizumab and drug-induced haemolytic uraemic syndrome ????Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=26120441 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26120441 #FOAvip English Wikipedia <ref>{{Cite pmid|26120441}}</ref> Eculizumab and drug-induced haemolytic?uraemic syndrome #MMPMID26120441 Faguer S; Huart A; Frémeaux-Bacchi V; Ribes D; Chauveau D Clin Kidney J 2013[Oct]; 6 (5): 484-5 PMID26120441show ga The monoclonal anti-C5 antibody eculizumab has been successfully tested in atypical haemolytic-uraemic syndrome (aHUS), with or without mutations in the regulatory proteins of the alternative pathway of the complement, and less convincingly in enterohaemorrhagic Escherichia coli-associated HUS. Here, we report a patient with mitomycin-C-induced HUS unresponsive to plasma exchanges. Eculizumab infusion was followed by a dramatic improvement of haematological parameters and renal function, suggesting a role of complement blockade in the management of refractory, drug-related HUS. äEculizumab and drug-induced haemolytic?uraemic syndrome (epmc).pdf DeepDyve Pubget Overpricing